Os therapies initiates commercial-ready manufacturing of ost-her2 to support anticipated biologics licensing authorization (bla) filing

New york--(business wire)--os therapies, inc. (nyse-a: ostx), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the commercial manufacture of ost-her2. the company is currently organizing additional data in relation to the recently-completed treatment phase of its phase 2b trial of ost-her2 in the prevention of recurrence of lung metastatic osteosarcoma in preparation for a.
OST Ratings Summary
OST Quant Ranking